![\"\"](\"https:\/\/lgmdcab.org\/wp-content\/uploads\/2026\/09\/2026_sept_askBio_DEF6_170x240-mm.jpeg\")
<\/figure>\n<\/div>\n\n\nKaya is living with LGMD2D\/R3 and participated in a gene therapy trial in 2015. He also has a degree in biomedical sciences and is currently studying Regenerative Medicine and Technology. This gives him a unique perspective. He understands the science behind gene therapy, but also the emotional, practical and personal questions that can come with it. The goal of this brochure and video series is not to replace conversations with doctors, specialists or care teams. Instead, it is meant to support those conversations. The videos can help explain key concepts, answer common questions, and make it easier to discuss this important topic with the people around you. You can watch the videos in your own time, return to them whenever needed, and share them with family members, friends or healthcare professionals. Together, this brochure and video series offer a simple and accessible way to learn more about LGMD-care, research, and the developments that may shape the future.<\/p>\n\n\n\n
Diagnostics as a steppingstone for treatment options<\/h1>\n\n\n\n
Before gene therapy or clinical trial eligibility can be discussed properly, doctors first need to understand the diagnosis as clearly as possible. For people with LGMD, this usually starts with confirming the exact genetic cause of the disease. A confirmed genetic diagnosis is important because LGMD is not one single disease. It is a group of genetic muscle diseases, and treatments or clinical trials are developed for specific LGMD subtypes. Alongside genetic testing, doctors may also use other tests to better understand how the disease affects the body. As a patient it is very important that you are aware of your LGMD subtype, this makes finding and receiving adequate care, and possibly treatments, much easier.<\/p>\n\n\n\n
Genetic diagnosis Muscle biopsy<\/strong> MRI<\/strong> Why these tests matter \u2018Gene therapy\u2019 is a broad term. It does not describe one single treatment. Different approaches work in different ways, depending on the disease, the gene, and the delivery method. LGMD is caused by mutations in specific genes. These genetic changes can lead to missing or faulty proteins that affect muscle function. Gene therapy aims to address part of this process by delivering genetic instructions to cells, using a delivery system called a \u2018vector\u2019. Many LGMD gene therapy studies use AAV vectors. These are adapted viruses designed to carry genetic material into the body, with the nucleus of muscle cells as target destination. After this genetic material enters the nucleus, it generally becomes a stable circular episome that can produce the missing protein for a long time, without integrating into the human DNA. Integration into the human DNA does happen, but at a very low frequency.\u00a0Other approaches, such as gene editing or different delivery systems such as non-viral lipid nanoparticles (LNPs), are also being researched. Gene therapy is a medical treatment with possible benefits, possible risks and many important\u00a0questions that need to be discussed carefully with a healthcare team prior to\u00a0treatment.<\/p>\n\n\n\n
<\/strong>To confirm an LGMD diagnosis, blood or saliva is tested. The test can look either at the whole DNA (WGS) or targeted gene panels. The identification of a variant does not necessarily mean that a diagnosis is confirmed, this depends on other factors, including the exact variant, the inheritance pattern and the clinical context. It is also possible that the test is inconclusive or shows a variant of unknown\u00a0significance (VUS). In these cases, further testing may be done. The database of known mutations is growing, so inconclusive results may be solved in the future.<\/p>\n\n\n\n
Before genetic testing, muscle biopsies were a big part of an LGMD diagnosis. A muscle biopsy is a test where a small piece of muscle tissue is taken and examined in a laboratory. Doctors may use it to look for signs of muscle damage or to study whether certain muscle proteins are present, reduced or missing. This can also be used to test the effect of gene therapy. It\u2019s very common that a trial includes a\u00a0baseline biopsy before the treatment and a biopsy a few months after gene therapy. Luckily, muscle biopsies can be taken with a small needle nowadays. This is less invasive than a traditional open muscle biopsy because the tissue is collected with a needle rather than a larger incision. Traditional biopsies may still be necessary for certain tests where a needle biopsy does not yield enough tissue or information.\u00a0<\/p>\n\n\n\n
MRI stands for Magnetic Resonance Imaging. An MRI scan can create detailed images of the muscles inside the body. MRI can help doctors see which muscles are affected and whether there is a pattern that fits a certain LGMD subtype. MRI may also help follow changes over time. For this reason, MRI testing is often part of a clinical trial too.<\/p>\n\n\n\n
<\/strong>Diagnostics are not only about giving the disease a name. They help patients, families and doctors understand the condition more clearly. The right diagnosis can support better follow-up care, help monitor changes over time and, in some cases, help determine whether someone may be eligible for a clinical trial or treatment option.<\/p>\n\n\n\nWhat is gene therapy?<\/h1>\n\n\n\n